Proteomic profiles of prevalent mild cognitive impairment and Alzheimer's disease among adults with Down syndrome

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring

Deborah Pang¹  Sharon J. Krinsky‐McHale¹  Melissa Petersen²  James Hall³  Sid E. O'Bryant³  Joseph H. Lee⁴  Nicole Schupf⁴  Wayne Silverman⁵  Fan Zhang⁶ 

[1]Department of Psychology NYS Institute for Basic Research in Developmental Disabilities Staten Island New York USA

[2]Institute for Translational Research Department of Family Medicine University of North Texas Health Science Center Fort Worth Texas USA

[3]Institute for Translational Research Department of Pharmacology and Neuroscience University of North Texas Health Science Center Fort Worth Texas USA

[4]Taub Institute for Research on Alzheimer's Disease and the Aging Brain Columbia University New York New York

[5]University of California Irvine California USA

[6]Vermont Genetics Network University of Vermont Burlington Vermont USA

关键词: blood based;    biomarkers;    plasma;    Down syndrome;    Alzheimer's disease;   

DOI  :  10.1002/dad2.12023

来源: DOAJ

【 摘 要 】

Abstract Introduction We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease (AD) in the general population would apply to adults with Down syndrome (DS). Methods Plasma samples were obtained from 398 members of a community‐based cohort of adults with DS. A total of n = 186 participants were determined to be non‐demented and without mild cognitive impairment (MCI) at baseline and throughout follow‐up; n = 50 had prevalent MCI; n = 42 had prevalent AD. Results The proteomic profile yielded an area under the curve (AUC) of 0.92, sensitivity (SN) = 0.80, and specificity (SP) = 0.98 detecting prevalent MCI. For detecting prevalent AD, the proteomic profile yielded an AUC of 0.89, SN = 0.81, and SP = 0.97. The overall profile closely resembled our previously published profile of AD in the general population. Discussion These data provide evidence of the applicability of our blood‐based algorithm for detecting MCI/AD among adults with DS.

【 授权许可】

Unknown